Pelecopan clinical trials
Also written BCX9930.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses pelecopan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BCX9930
- 5
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses pelecopan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTerminatedPhase 2BioCryst PharmaceuticalsNCT05116774Written as BCX9930
- Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)TerminatedPhase 2BioCryst PharmaceuticalsNCT05162066Written as BCX9930
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyTerminatedPhase 2BioCryst PharmaceuticalsNCT05116787Written as BCX9930 monotherapy
- Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 2BioCryst PharmaceuticalsNCT05741346Written as BCX9930
- A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedPhase 2BioCryst PharmaceuticalsNCT04702568Written as BCX9930
- First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHCompletedPhase 1/2BioCryst PharmaceuticalsNCT04330534Written as BCX9930
Codes
What other systems call pelecopan · ClinicalTrials.gg INT016940
- UNII (FDA) JD988C0G6JPELECOPANOne source FDA
- NCI Thesaurus C176745PelecopanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JD988C0G6J | PELECOPAN | One source FDA |
| NCI Thesaurus | C176745 | Pelecopan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.